Giovanni Taccetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6916467/publications.pdf

Version: 2024-02-01

61	2,238	361413	223800
papers	citations	20	46
		h-index	g-index

65	65	65	2970
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sindrome da perdita di sali e infezione da Clostridium difficile nella fibrosi cistica. Medico E Bambino Pagine Elettroniche, 2022, 25, 21-22.	0.0	0
2	Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society. Infection, 2022, 50, 671-679.	4.7	20
3	Tobramycin safety and efficacy review article. Respiratory Medicine, 2022, 195, 106778.	2.9	5
4	Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. Journal of Cystic Fibrosis, 2022, 21, 850-855.	0.7	12
5	The Risks of Complications During Endoscopic Sinus Surgery in Cystic Fibrosis Patients: An Anatomical and Endoscopic Study. Laryngoscope, 2021, 131, E2481-E2489.	2.0	5
6	Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present. Italian Journal of Pediatrics, 2021, 47, 2.	2.6	4
7	Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics, 2021, 10, 338.	3.7	50
8	Effectiveness of enteral nutrition by percutaneous endoscopic gastrostomy in malnourished patients with cystic fibrosis: Does the gender gap play a role?. Nutrition in Clinical Practice, 2021, 36, 907-908.	2.4	0
9	Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice. Italian Journal of Pediatrics, 2021, 47, 168.	2.6	7
10	Six minute walk test in Italian children with cystic fibrosis aged 6 and 11. Monaldi Archives for Chest Disease, 2021, , .	0.6	1
11	A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials. Journal of Cystic Fibrosis, 2020, 19, 52-67.	0.7	9
12	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
13	Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease. Microorganisms, 2020, 8, 1003.	3.6	23
14	Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy. Diagnostics, 2020, 10, 446.	2.6	22
15	Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function. Respiratory Medicine, 2020, 171, 106073.	2.9	23
16	Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS ONE, 2019, 14, e0213497.	2.5	22
17	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.7	521
18	Chronic infection sustained by a Pseudomonas aeruginosa High-Risk clone producing the VIM-1 metallo-Î²-lactamase in a cystic fibrosis patient after lung transplantation. Journal of Cystic Fibrosis, 2018, 17, 470-474.	0.7	5

#	Article	IF	Citations
19	Mycobacterium abscessusin patients with cystic fibrosis: low impact of inter-human transmission in Italy. European Respiratory Journal, 2017, 50, 1602525.	6.7	63
20	A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients with Severe Lung Disease. International Journal of Molecular Sciences, 2017, 18, 1654.	4.1	39
21	Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov.. International Journal of Systematic and Evolutionary Microbiology, 2016, 66, 4471-4479.	1.7	190
22	Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline. PLoS ONE, 2016, 11, e0156807.	2.5	29
23	Within-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients. BMC Microbiology, 2015, 15, 218.	3.3	62
24	An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulmonary Medicine, 2015, 15, 116.	2.0	23
25	Changes in Cystic Fibrosis Airway Microbial Community Associated with a Severe Decline in Lung Function. PLoS ONE, 2015, 10, e0124348.	2.5	59
26	Genomes analysis and bacteria identification: The use of overlapping genes as molecular markers. Journal of Microbiological Methods, 2015, 117, 108-112.	1.6	9
27	Bacterial Lung Infections in Cystic Fibrosis Patients. Pediatric Infectious Disease Journal, 2014, 33, 653-654.	2.0	21
28	Early detection of infection with Pseudomonas aeruginosa in cystic fibrosis: The Holy Grail or an achievable goal?. Journal of Cystic Fibrosis, 2014, 13, 491-493.	0.7	4
29	Evaluation of specific immune response in early P. aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis, 2014, 13, 116-117.	0.7	1
30	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.7	438
31	Early antibiotic treatment forPseudomonas aeruginosaeradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax, 2012, 67, 853-859.	5.6	92
32	Lactate in cystic fibrosis sputum. Journal of Cystic Fibrosis, 2011, 10, 37-44.	0.7	59
33	Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax, 2011, 66, 260-261.	5.6	31
34	A 1-m distance is not safe for children with cystic fibrosis at risk for cross-infection with Pseudomonas aeruginosa. American Journal of Infection Control, 2010, 38, 244-245.	2.3	9
35	Community-associated meticillin-resistant Staphylococcus aureus. Lancet, The, 2010, 376, 767-768.	13.7	9
36	Methicillin resistant staphylococcus aureus in cystic fibrosis. Pediatric Pulmonology, 2008, 43, 309-309.	2.0	5

#	Article	IF	Citations
37	Incidence of cystic fibrosis in the Albanian population. Pediatric Pulmonology, 2008, 43, 1124-1129.	2.0	6
38	Use of the gyrB gene to discriminate among species of the Burkholderia cepacia complex. FEMS Microbiology Letters, 2008, 281, 175-182.	1.8	20
39	Emergence of an Epidemic Clone of Community-Associated Methicillin-Resistant Panton-Valentine Leucocidin-Negative Staphylococcus aureus in Cystic Fibrosis Patient Populations. Journal of Clinical Microbiology, 2007, 45, 3146-3147.	3.9	17
40	Exopolysaccharides produced by clinical strains belonging to the Burkholderia cepacia complex. Journal of Cystic Fibrosis, 2007, 6, 145-152.	0.7	24
41	Patient risk of contact with respiratory pathogens from inanimate surfaces in a cystic fibrosis outpatient clinic. A prospective study over a fourâ€year period. Pediatric Pulmonology, 2007, 42, 779-784.	2.0	8
42	Evidence supporting isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis. Journal of Hospital Infection, 2007, 65, 375-376.	2.9	1
43	Use of continuous subcutaneous insulin infusion in cystic fibrosis patients with cystic fibrosis-related diabetes awaiting transplantation. Journal of Cystic Fibrosis, 2006, 5, 67-68.	0.7	12
44	Alteration of Bone Mineral Density in Cystic Fibrosis Adults. Chest, 2006, 130, 1952-1953.	0.8	7
45	Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment. Journal of Maternal-Fetal and Neonatal Medicine, 2006, 19, 375-376.	1.5	6
46	Gestational and Neonatal Characteristics of Children with Cystic Fibrosis: A Cohort Study. Journal of Pediatrics, 2005, 147, 316-320.	1.8	37
47	Clinical follow-up of 122 Italian cystic fibrosis patients with B. cepacia complex colonisation. Journal of Cystic Fibrosis, 2005, 4, 145-146.	0.7	1
48	National scientific associations should have a key role in adapting and implementing standard of care guidelines in European countries. Journal of Cystic Fibrosis, 2005, 4, 271-272.	0.7	0
49	Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. Journal of Cystic Fibrosis, 2004, 3, 159-163.	0.7	44
50	Neonatal screening for cystic fibrosis and Pseudomonas aeruginosa acquisition. Journal of Pediatrics, 2004, 145, 421.	1.8	3
51	To the editor: Gender differences in the acquisition ofP. aeruginosa. Pediatric Pulmonology, 2003, 36, 453-454.	2.0	1
52	Bicycle Racing. New England Journal of Medicine, 2003, 348, 566-567.	27.0	0
53	Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients. Lancet, The, 2002, 359, 625-626.	13.7	19
54	Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria. European Journal of Epidemiology, 2000, 16, 837-842.	5.7	22

#	Article	IF	Citations
55	Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. European Journal of Epidemiology, 1999, 15, 85-88.	5.7	24
56	Autoantibodies against bactericidal/permeability-increasing protein in cystic fibrosis patients: Comment on the article by Hoffman and Specks. Arthritis and Rheumatism, 1999, 42, 1305-1306.	6.7	3
57	Microbiologic data overview of Italian cystic fibrosis patients. , 1997, 13, 323-327.		14
58	Methotrexate-associated appearance and rapid progression of rheumatoid nodules in systemic-onset juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 175-178.	6.7	65
59	Pseudomonas aeruginosa infection in patients with cystic fibrosis. Journal of Pediatrics, 1996, 129, 619-620.	1.8	0
60	Efficacy and safety of immunoglobulin retreatment in Kawasaki disease. Journal of Pediatrics, 1994, 125, 672-673.	1.8	3
61	Myocardial infarction in a girl with primary antiphospholipid syndrome. Journal of Pediatrics, 1991, 119, 332.	1.8	1